SMARCA4 and undifferentiated carcinoma: Patients with undifferentiated carcinoma of the gastrointestinal (GI) tract exhibiting loss of SMARCA4 expression demonstrated significantly poorer overall survival (p = 0.028) and disease-free survival (p = 0.006) compared to those with SMARCA4 expression [7].